Sign up Australia
Proactive Investors - Run By Investors For Investors

Invion teams with Hudson Institute to advance light-based cancer therapy research

Initial projects will focus on ovarian cancer and will expand into other cancer indications.
cancer cells
Light-based therapy to kill cancer cells

Invion Ltd (ASX:IVX) has signed a research and development (R&D) agreement with leading Australian medical research institute, Hudson Institute of Medical Research.

The agreement provides a framework for Invion and Hudson Institute to collaborate on R&D projects based on Invion’s Photosoft technology for the treatment of cancers.

Light-based therapy to kill cancer cells

Invion is developing Photosoft as a next generation photo dynamic therapy (PDT).

PDT uses non-toxic photosensitisers and visible light in combination with oxygen to kill malignant cells, shut down tumours and to stimulate the immune system.

In contrast to surgery, radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation and invasion of a tumour by leukocytes.

Targeting circulating cancer cells and deeply seated tumours

Photosoft is targeted to address the limitations of first-generation PDT therapies through better solubility and stronger absorption that allows deeper penetration of tissues and better tumour specificity.

Invion’s Photosoft uses a laser light activation method based on short, pulsating ‘near infrared’ (NIR) wavelengths.

It is hypothesised that NIR light therapy allows more effective whole-of-body systemic treatment that can target circulating cancer cells as well as deeply seated tumours.

Initial projects to focus on ovarian cancer

Under the new agreement, Hudson Institute will provide the research facilities and expertise required to undertake individual Invion-sponsored research projects.

Furthermore, Hudson Institute will be responsible for all legislative and professional standards compliance requirements, in accordance with global best practice.

Initial projects will focus on ovarian cancer, and it is envisioned that projects will quickly expand into other cancer indications.

READ: Invion's strategic alliance with Cho Group provides distribution opportunities

Invion has an agreement with The Cho Group to conduct clinical development of Photosoft globally.

The Cho Group will provide non-dilutive funding to Invion for R&D and clinical trials as part of a global development strategy for the asset.

View full IVX profile View Profile

Invion Ltd Timeline

Newswire
September 01 2015
Newswire
August 28 2015

Related Articles

tumour cells
July 25 2018
Sign-off by the US Food & Drug Administration is considered the "global standard for approval", the company said
1528098797_Biotech-lab.jpg
June 05 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use